These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1647992)

  • 1. Expression of functional human Epstein-Barr virus/C3d receptor ([CR2] CD21) on insulinoma cell line. Induction of tumor rejection but not diabetes in syngeneic rats.
    Carel JC; Holers VM; Chick WL; Littman D; Lacy PE
    Diabetes; 1991 Jul; 40(7):809-14. PubMed ID: 1647992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23.
    Cordier M; Calender A; Billaud M; Zimber U; Rousselet G; Pavlish O; Banchereau J; Tursz T; Bornkamm G; Lenoir GM
    J Virol; 1990 Mar; 64(3):1002-13. PubMed ID: 2154588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of epitope expression and the functional repertoire of recombinant complement receptor 2 (CR2/CD21) in mouse and human cells.
    Carel JC; Frazier B; Ley TJ; Holers VM
    J Immunol; 1989 Aug; 143(3):923-30. PubMed ID: 2473114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stable expression and function of EBV/C3d receptor following genomic transfection into murine fibroblast L cells.
    Cantaloube JF; Piechaczyk M; Calender A; Lenoir G; Minty A; Carrière D; Fischer E; Poncelet P
    Eur J Immunol; 1990 Feb; 20(2):409-16. PubMed ID: 1690137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection.
    Carel JC; Myones BL; Frazier B; Holers VM
    J Biol Chem; 1990 Jul; 265(21):12293-9. PubMed ID: 1695627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus (EBV) infection of murine L cells expressing recombinant human EBV/C3d receptor.
    Ahearn JM; Hayward SD; Hickey JC; Fearon DT
    Proc Natl Acad Sci U S A; 1988 Dec; 85(23):9307-11. PubMed ID: 2848261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble recombinant CR2 (CD21) inhibits Epstein-Barr virus infection.
    Nemerow GR; Mullen JJ; Dickson PW; Cooper NR
    J Virol; 1990 Mar; 64(3):1348-52. PubMed ID: 2154612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein Barr virus/complement C3d receptor is an interferon alpha receptor.
    Delcayre AX; Salas F; Mathur S; Kovats K; Lotz M; Lernhardt W
    EMBO J; 1991 Apr; 10(4):919-26. PubMed ID: 1849076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction between Epstein-Barr virus and a T cell line (HSB-2) via a receptor phenotypically distinct from complement receptor type 2.
    Hedrick JA; Watry D; Speiser C; O'Donnell P; Lambris JD; Tsoukas CD
    Eur J Immunol; 1992 May; 22(5):1123-31. PubMed ID: 1315687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C3d and Epstein-Barr virus (CR2/CD21 ligands) stimulate cells of an HTLV-I line, MT-2.
    Kuraya M; Sato T; Fujita T
    Microbiol Immunol; 1995; 39(2):145-51. PubMed ID: 7783687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus (EBV)-containing nasopharyngeal carcinoma cells express the B-cell activation antigen blast2/CD23 and low levels of the EBV receptor CR2.
    Billaud M; Busson P; Huang D; Mueller-Lantzch N; Rousselet G; Pavlish O; Wakasugi H; Seigneurin JM; Tursz T; Lenoir GM
    J Virol; 1989 Oct; 63(10):4121-8. PubMed ID: 2550660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rejection of islets differing by a single antigen is dependent on donor MHC.
    Vigneau-Hermellin M; Vitali L; Tardivel I; Rabaud M; Holers MV; Carel JC
    Diabetes; 1997 May; 46(5):765-9. PubMed ID: 9133542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Epstein-Barr virus infection in vitro and in vivo by soluble CR2 (CD21) containing two short consensus repeats.
    Moore MD; Cannon MJ; Sewall A; Finlayson M; Okimoto M; Nemerow GR
    J Virol; 1991 Jul; 65(7):3559-65. PubMed ID: 1645784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21).
    Ahearn JM; Fearon DT
    Adv Immunol; 1989; 46():183-219. PubMed ID: 2551147
    [No Abstract]   [Full Text] [Related]  

  • 15. Genomic organization and polymorphisms of the human C3d/Epstein-Barr virus receptor.
    Fujisaku A; Harley JB; Frank MB; Gruner BA; Frazier B; Holers VM
    J Biol Chem; 1989 Feb; 264(4):2118-25. PubMed ID: 2563370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of Epstein-Barr virus-binding sites on complement receptor 2 (CR2/CD21) using human-mouse chimeras and peptides. At least two distinct sites are necessary for ligand-receptor interaction.
    Molina H; Brenner C; Jacobi S; Gorka J; Carel JC; Kinoshita T; Holers VM
    J Biol Chem; 1991 Jul; 266(19):12173-9. PubMed ID: 1712014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies of the Epstein Barr virus receptor found on Raji cells. II. A comparison of lymphocyte binding sites for Epstein Barr virus and C3d.
    Hutt-Fletcher LM; Fowler E; Lambris JD; Feighny RJ; Simmons JG; Ross GD
    J Immunol; 1983 Mar; 130(3):1309-12. PubMed ID: 6218205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic modification of an islet tumor cell line inhibits its rejection.
    Georgiou HM; Brady JL; Silva A; Lew AM
    Transplant Proc; 1997; 29(1-2):1032-3. PubMed ID: 9123184
    [No Abstract]   [Full Text] [Related]  

  • 19. Insulin secretion in vivo and in vitro from transplantable NEDH rat insulinoma and derived clonal RINm5F cell line.
    Flatt PR; DeSilva M; Swanston-Flatt SK; Marks V
    Diabetes Res; 1987 Oct; 6(2):85-90. PubMed ID: 2827934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the human complement receptor 2 (CR2, CD21) promoter reveals sequences shared with regulatory regions of other developmentally restricted B cell proteins.
    Rayhel EJ; Dehoff MH; Holers VM
    J Immunol; 1991 Mar; 146(6):2021-6. PubMed ID: 1706386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.